U.S. states sue drug companies for price-fixing scheme
The lawsuit names 15 medicines that treat conditions ranging from diabetes to rheumatoid arthritis to hypertension.
The companies targeted in the lawsuit include Mylan, the maker of asthma treatment EpiPen, and Teva Pharmaceuticals that sells the multiple sclerosis drug Copaxone.
Mylan president Rajiv Malik and Satish Mehta, the chief executive of Emcure Pharmaceuticals that is based in India, were named in the lawsuit.
The states allege the drug companies conspired to split up the generic drug market, fix prices and avoid competing with each other.
The lawsuit is being led by Connecticut Attorney General George Jepsen.
“It is our belief that price-fixing is systematic. It is pervasive, and that a culture of collusion exists in the industry,” Jepsen said at a news conference.
He said states are looking into targeting nine additional companies. The suit has greatly expanded since it was initially filed last December and named just two drugs and seven companies.
The price of drugs has caused a storm of controversy in the past few years, especially regarding price increases for the EpiPen. ■